Загрузка...
Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30
An awesome number of experimental and clinical evidences indicate that constitutive activation of the Met oncogenic receptor plays a critical role in the progression of cancer toward metastasis and/or resistance to targeted therapies. While mutations are rare, the common mechanism of Met activation...
Сохранить в:
| Опубликовано в: : | Mol Oncol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528712/ https://ncbi.nlm.nih.gov/pubmed/26119717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.05.007 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|